- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05582772
TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer (TOPCOP3)
TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer (TOPCOP3): a Pilot RCT and Process Evaluation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Emerging data from supportive care intervention trials in people receiving chemotherapy suggest 2 different approaches - geriatric assessment and management (GA+M) and remote symptom monitoring (RSM) - may be associated with improved time on treatment, improved QOL, reduced toxicity, reduced unplanned health care use, and possibly prolonged overall survival. These 2 interventions have not been tested in combination or in people receiving treatments other than chemotherapy (such as ARATs). This RCT includes an embedded process evaluation of GA+M and RSM versus usual care to gather key efficacy and implementation data needed to design a definitive phase III RCT.
The next logical step in our research program is an intervention examining GA+M, RSM, or the combined intervention to improve the health and treatment tolerability for older men with mPC on ARATs. The pilot trial will gather key clinical outcome and feasibility data needed to inform a definitive phase III RCT; a necessary step in providing clinicians a greatly needed evidence-based supportive care intervention. The intervention was designed in partnership with patients and knowledge users, which will result in more relevant findings and greater health impact.
A total of 168 patients will be enrolled in the RCT across 2 centres. Based on TOPCOP1 and TOPCOP2, both of which included the two centres in TOPCOP3, the recruitment rate was 2-3 patients per week. There are 3-5 eligible patients per week across the two sites. Assuming a conservative recruitment rate of 50%, the investigators expect recruitment for this study to take 18 months.
Randomization will be centralized using REDCap, a secure web-based electronic data entry system. Patients will be allocated in a 1:1:1:1 ratio to GA+M, RSM, combined, or control, with stratification by mPC subtype (castration-sensitive or resistant) following recommended guidelines on number of strata. Permuted blocks of variable size will be used.
Given the nature of the intervention, it is not possible to blind patients or the project team to allocation. However, participants will be randomized, allocation will be concealed, variable permuted blocks will be used, 1 of the 2 co-primary outcomes will be assessed by blinded assessors (toxicity), validated measures will be used, several outcomes will be verified by independent data collection (treatment toxicity, overall survival), and the trial statistician will be blinded during the trial and during analysis of the main study results, similar to our 5C trial.
GA+M intervention arm:
All participants in the GA+M intervention arm will undergo a standardized GA by a trained nurse and geriatrician. The GA will include 8 domains (comorbidity, medication review, function, falls risk, nutrition, social supports, cognition, and mood) similar to our 5C protocol.
Based on any detected abnormalities or issues, a standardized set of strategies will be implemented (e.g. increased falls risk will lead to detailed assessment of balance and gait, consideration of gait aid, and referral to outpatient physiotherapy). This follows the standard approach to implementing GA similar to recent trials in geriatric oncology including 5C.Telephone follow-ups at 1, 3 and 6 months by the nurse and review with the geriatrician as needed will be done to ensure identified issues have been addressed.
RSM Intervention arm:
All participants in the RSM intervention arm will receive once-weekly symptom monitoring via email-based surveys using the 9-item Edmonton Symptom Assessment Scale within a secure customized REDCap interface. If patients prefer, weekly telephone calls will be done instead by a research assistant to elicit symptoms. In our prior study, almost half the participants preferred telephone calls. If there are moderate or severe symptoms (score of 4+ out of 10), an oncology nurse will obtain more detailed symptom information and provide evidence-based symptom-targeted recommendations using the pan-Canadian Oncology Symptom Triage and Remote Support (COSTaRS) Practice Guide. For moderate symptoms that persist even after follow up, if the RSM nurse feels that the patient is clinically stable in the same symptom based on at least 2 phone assessments, 1 week apart, and there are no further COSTaRS-directed interventions to be implemented for this symptom based on the RSM nurse's judgement the following silencing protocol can be adopted: The RSM nurse will inform the study coordinator to not flag the study nurse for further moderate alerts for the same symptom if the score is identical to the prior week (i.e. to silence the alarm). If the score changes from moderate to severe, or increases 2 points within the same verbal descriptor severity category (e.g. 4 to 6/10, both are moderate) then the nurse is alerted again. The silencing option will remain for 4 weeks then expire. Symptom monitoring will continue for 6 months or discontinuation of treatment (whichever comes first). If treatment is discontinued for a period of 3 weeks, the weekly ESAS questionnaire will not be sent out to the participant until treatment is resumed. An escalation protocol will also be followed for persistent symptoms or those deemed out of scope for nurse-guided self-management, with referral to the patient's oncologist or urgent care as appropriate. Oncology nurses are ideally situated to be the primary point of contact with oncology patients, can promote patient self-efficacy, provide counselling and support, and can handle 87% of issues without needing physician input.
GA+RSM Combination:
Participants will receive both strategies as detailed above, with a GA at baseline.
Control:
Usual care consists of brief verbal education and a drug pamphlet to all patients when starting an ARAT. There is no GA+M and no RSM at either site. Patients have access to a 24x7 oncology nursing line.
Patients will receive the TOPCOP3 intervention for a duration of 6 months. This balances participant burden and resources with a timeframe that is sufficient to observe clinical and implementation outcomes (most severe toxicity is observed within the first 3 months of treatment. Most GA+M trials have been 6 months in duration.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Shabbir Alibhai, MD
- Phone Number: (416) 340-5125
- Email: shabbir.alibhai@uhn.ca
Study Contact Backup
- Name: Soha Abdallah
- Phone Number: 3926 416-946-4501
- Email: soha.abdallah@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- Recruiting
- Sunnybrook Health Sciences Centre
-
Principal Investigator:
- Urban Emmenegger, MD
-
Sub-Investigator:
- Martin Smoragiewicz, MD
-
Contact:
- Urban Emmenegger, MD
- Phone Number: 416-480-4928
- Email: urban.emmenegger@sunnybrook.ca
-
Toronto, Ontario, Canada, M5G 2C1
- Recruiting
- University Health Network - Princess Margaret Cancer Centre
-
Contact:
- Shabbir Alibhai, MD
- Phone Number: 4163405125
- Email: shabbir.alibhai@uhn.ca
-
Principal Investigator:
- Shabbir Alibhai, MD
-
Sub-Investigator:
- Jacqueline Bender, PhD
-
Sub-Investigator:
- Alejandro Berlin, MD
-
Sub-Investigator:
- Rana Jin, RN, Msc
-
Sub-Investigator:
- Monika Krzyzanowska, MD, MPH
-
Sub-Investigator:
- Calvin Mach, RD, MPH
-
Sub-Investigator:
- Andrew Matthew, PhD
-
Sub-Investigator:
- Lesley Moody, PhD
-
Sub-Investigator:
- Efthymios Papadopoulos, PhD
-
Sub-Investigator:
- Enrique Soto Perez de Celis, MD
-
Sub-Investigator:
- George Tomlinson, PhD
-
Sub-Investigator:
- Rachel Glicksman, MD
-
Sub-Investigator:
- Antonio Finelli, MD
-
Sub-Investigator:
- Srikala Sridhar, MD
-
Contact:
- Soha Abdallah
- Phone Number: 3926 416-946-4501
- Email: soha.abdallah@uhn.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Starting an ARAT or started an ARAT within 2 weeks prior to being approached or switching ARATs due to progression or toxicity
- Diagnosed with mPC (castration-sensitive or resistant) or nmCRPC (non-metastatic castration-resistant prostate cancer)
- At least 65 years old
- Able to provide written informed consent
- Has a working telephone
Exclusion Criteria:
- Unable to speak English (as contact with the nurse interventionist is via phone, not all outcome measures are available in multiple languages)
- Major neuropsychiatric abnormalities (severe depression or moderate-severe dementia)
- Life expectancy <3 months as estimated by the oncologist
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: RSM Intervention
RSM Intervention All participants in the RSM intervention arm will receive once-weekly symptom monitoring via email-based surveys using the 9-item Edmonton Symptom Assessment Scale within a secure customized REDCap interface.
If patients prefer, weekly telephone calls will be done instead by a research assistant to elicit If there are moderate or severe symptoms (score of 4+ out of 10), an oncology nurse will obtain more detailed symptom information and provide evidence-based symptom-targeted recommendations using the pan-Canadian Oncology Symptom Triage and Remote Support (COSTaRS) Practice Guide.
Symptom monitoring will continue for 6 months or discontinuation of treatment.
|
Telephone-based, symptom management of patients with cancer
Other Names:
|
Active Comparator: GA+RSM intervention
GA+RSM Combination Participants will receive both strategies as detailed above, with a GA at baseline.
|
Combining a geriatric assessment and remote symptom control
Other Names:
|
No Intervention: Control
Control Usual care consists of brief verbal education and a drug pamphlet to all patients when starting an ARAT.
There is no GA+M and no RSM at either site.
Patients have access to a 24x7 oncology nursing line or a 24/7 pharmacy line.
|
|
Active Comparator: GA+M Intervention
GA+M intervention arm All participants in the GA+M intervention arm will undergo a standardized GA by a trained nurse and geriatrician. The GA will include 8 domains (comorbidity, medication review, function, falls risk, nutrition, social supports, cognition, and mood) similar to our 5C protocol. Based on any detected abnormalities or issues, a standardized set of strategies will be implemented (e.g. increased falls risk will lead to detailed assessment of balance and gait, consideration of gait aid, and referral to outpatient physiotherapy). This follows the standard approach to implementing GA similar to recent trials in geriatric oncology including 5C. Telephone follow-ups at 1, 3 and 6 months by the nurse and review with the geriatrician as needed will be done to ensure identified issues have been addressed. |
Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician.
A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO).
For a GA to be most useful it needs to be followed by co-management of identified issues.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with Grade 3-5 Toxicity
Time Frame: 6 months
|
Grade 3-5 toxicity.
This will be coded as at least one grade 3-5 toxicity vs none, measured based on review of clinical notes supplemented by interviews with patients by trained research staff and verified by a blinded physician.
Toxicities will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
|
6 months
|
Health related quality of life in patients with metastatic prostate cancer
Time Frame: 6 months
|
QOL will be measured by patient self-report using the EQ-5D-5L, which is the EuroQol 5 dimensions of health questionnaire.
This is a widely used, psychometrically valid brief generic QOL questionnaire.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with treatment discontinuation
Time Frame: 6 months
|
Early treatment discontinuation due to toxicity.
This will be based on chart review and oncologist clarification.
|
6 months
|
Number of patients with treatment modification
Time Frame: 6 months
|
Treatment modification after GA (change in ARAT dose/agent).
Based on chart review.
For GA+M arms only
|
6 months
|
Number of patients with severe symptoms
Time Frame: 6 months
|
Symptom severity.
This is measured using the 15-item Symptom Distress Scale.
This is a patient reported outcome (PRO).
|
6 months
|
Number of patients with decline in Instrumental Activities of Daily Living (IADL)
Time Frame: 6 months
|
Decline in IADL using the Older Adults Resources and Services (OARS) scale.
This is a patient reported outcome (PRO).
|
6 months
|
Number of patients with unplanned health care
Time Frame: 6 months
|
Unplanned health care use.
Emergency room visits and hospital admissions will be recorded at each time point with a combination of patient interviews and electronic health record audit
|
6 months
|
Fatigue
Time Frame: 6 months
|
Fatigue - measured using the Brief Fatigue Inventory (BFI).
This is a patient reported outcome (PRO).
|
6 months
|
Insomnia
Time Frame: 6 months
|
Insomnia will be measured using the Insomnia Severity Index.
This is a patient reported outcome (PRO).
|
6 months
|
Anorexia and cachexia
Time Frame: 6 months
|
Anorexia and Cachexia is measured with the Functional Assessment of Anorexia-Cachexia Therapy scale (Functional Assessment of Anorexia/Cachexia FAACT-A/CS-12).
This is a patient reported outcome (PRO).
|
6 months
|
Depression
Time Frame: 6 months
|
Depression will be measured using the 9-item Patient Health Questionnaire (PHQ-9).
This is a patient reported outcome (PRO).
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Process evaluation: Feasibility
Time Frame: 6 months
|
The trial will be determined to be feasible if recruitment rate is 60% or higher, retention rate is 85% or higher, adherence is 90% or higher, outcome capture is 90% or higher, and contamination rate is 5% or less.
|
6 months
|
Process evaluation: Acceptability
Time Frame: 6 months
|
Likert scale satisfaction survey.
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shabbir Alibhai, MD, UHN - Princess Margaret Cancer Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4090 (OPD)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Prostate Cancer
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
Tavanta TherapeuticsCompletedMetastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
-
Bellicum PharmaceuticalsSuspendedMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
WntResearch ABCompletedMetastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Colon CancerDenmark, United Kingdom
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.Active, not recruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate NeoplasmUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationRecruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Sumitomo Pharma Switzerland GmbHActive, not recruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
Clinical Trials on GA+M Intervention
-
University of RochesterCompletedCancerUnited States
-
Charles G. ProberStanford University; Heidelberg University; University of Stellenbosch; University...CompletedExclusive Breastfeeding | Infant Feeding PracticesSouth Africa
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University HospitalRecruitingCentral Line-associated Bloodstream Infection (CLABSI)Denmark
-
Universidad del DesarrolloInstituto Milenio para Investigación en Depresión y Personalidad; Peñalolén...RecruitingDepression, Postpartum | Anxiety Disorders and Symptoms | Maternal BehaviorChile
-
Augusta UniversityUniversity of Michigan; Henry Ford Health SystemCompleted
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)Not yet recruiting
-
Kathmandu University School of Medical SciencesNot yet recruitingBirth Outcomes | Infant HealthNepal
-
Assistance Publique - Hôpitaux de ParisNational Cancer Institute, France; Canceropôle Ile de France; Oncogeriatric Coordination... and other collaboratorsRecruiting
-
First Affiliated Hospital of Fujian Medical UniversityRecruiting